Salix Pharmaceuticals Ltd. Sustainability Profile
Salix Pharmaceuticals Ltd., a prominent player in the pharmaceutical industry, is headquartered in the United States and focuses primarily on gastrointestinal disorders. Founded in 2001, the company has made significant strides in developing innovative therapies that address unmet medical needs, particularly in the areas of irritable bowel syndrome and inflammatory bowel disease. Salix is renowned for its core products, including prescription medications that offer unique mechanisms of action, setting them apart in a competitive market. With a strong commitment to research and development, Salix has achieved notable milestones, solidifying its position as a leader in gastrointestinal health. The company continues to expand its operational reach, serving patients across North America and beyond, while maintaining a focus on delivering high-quality, effective treatments.
DitchCarbon Score
How does Salix Pharmaceuticals Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Salix Pharmaceuticals Ltd.'s score of 40 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Salix Pharmaceuticals Ltd., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Bausch Health Companies Inc., which may influence its climate commitments and reporting practices. While there are no documented reduction targets or climate pledges specific to Salix Pharmaceuticals, it is important to note that any potential climate initiatives or targets would likely be aligned with those set by its parent company, Bausch Health Companies Inc. This includes commitments to sustainability and emissions reduction that may cascade down to Salix Pharmaceuticals. As of now, Salix Pharmaceuticals has not disclosed any specific initiatives or targets related to the Science Based Targets initiative (SBTi) or other industry-standard climate frameworks. The lack of emissions data and reduction commitments highlights an opportunity for the company to enhance its environmental accountability and transparency in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 46,686,000 | 00,000,000 |
| Scope 2 | 50,513,000 | 00,000,000 |
| Scope 3 | 19,260,000 | 00,000,000 |
How Carbon Intensive is Salix Pharmaceuticals Ltd.'s Industry?
How Carbon Intensive is Salix Pharmaceuticals Ltd.'s Location?
Salix Pharmaceuticals Ltd.'s Scope 3 Categories Breakdown
Salix Pharmaceuticals Ltd.'s Scope 3 emissions, which increased by 41% last year and increased by approximately 41% since 2022, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 21% of total emissions under the GHG Protocol, with "Waste Generated in Operations" representing nearly all of their reported Scope 3 footprint.
Top Scope 3 Categories
Salix Pharmaceuticals Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Salix Pharmaceuticals Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
